
|Articles|July 10, 2015
- Gastrointestinal Cancers (Issue 5)
- Volume 4
- Issue 2
Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials
Author(s)Axel Grothey, MD
Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.
Advertisement
Articles in this issue
over 10 years ago
Prevention and Screening of CRCover 10 years ago
Survival Differences in KRAS/BRAF Mutations in mCRCover 10 years ago
New Agents Show Potency for Patients with HCCover 10 years ago
Success of Regorafenib Confirmed in Patients With mCRCover 10 years ago
Agents Under Examination Demonstrate Success in Gastric CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5










































